Shinjiro Fukami

Dr. Shinjiro Fukami


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2023 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Open access
SFShinjiro Fukami
Shinjiro Fukami
JAJiro Akimoto
Jiro Akimoto
KNKenta Nagai
Kenta Nagai
YSYuki Saito
Yuki Saito
MKMichihiro Kohno
Michihiro Kohno
For malignant glioma, intraoperative photodynamic therapy (PDT) using talaporfin sodium is a powerful tool for local tumor control, when gross total removal is performed. However, the efficacy of PDT for non-totally resectable malignant glioma has not been clearly confirmed. Therefore, the purpose of this study was to clarify the usefulness of PDT using talaporfin sodium for non-totally resectable malignant glioma. Eighteen patients with malignant glioma (16 new onset, 2 recurrent) in whom gross total removal was judged to be difficult from the images obtained before surgery were evaluated. Fifteen patients had glioblastoma (14 newly diagnosed, 1 recurrent), and 3 patients had anaplastic oligodendroglioma (2 newly diagnosed, 1 recurrent). The whole resection cavity was subjected to PDT during the surgery. For newly diagnosed glioblastoma, postoperative therapy involved the combined use of radiation and temozolomide. Bevacizumab treatment was also started at an early stage after surgery. In some patients, reduction of the residual tumor was observed at an early stage of chemoradiotherapy after the surgery, suggesting the positive effect of PDT. Recurrence occurred in 15 of the 18 patients during the course of treatment. Distant recurrence occurred in 8 of these 15 patients, despite good local tumor control. In the 14 patients with newly diagnosed glioblastoma, the median progression-free survival was almost 10.5 months, and the median overall survival was almost 16.9 months. PDT for malignant glioma is expected to slightly improve local tumor control for non-totally resectable lesions.

20 September 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
YSYuki Saito
Yuki Saito
SFShinjiro Fukami
Shinjiro Fukami
KNKenta Nagai
Kenta Nagai
EOEmiyu Ogawa
Emiyu Ogawa
MKMasahiko Kuroda
Masahiko Kuroda
Jiro AkimotoJiro Akimoto
Jiro Akimoto
This preclinical study was conducted to investigate the efficacy of interstitial PDT (i-PDT) for malignant gliomas arising deep within the brain, which are difficult to remove. C6 glioma cells were implanted into the basal ganglia of rats, and 3 weeks later, the second-generation photosensitizer talaporfin sodium (TPS) was administered intraperitoneally. Ninety minutes after administration, a prototype fine plastic optical fiber was punctured into the tumor tissue, and semiconductor laser light was irradiated into the tumor from a 2-mm cylindrical light-emitting source under various conditions. The brain was removed 24 h after the i-PDT and analyzed pathologically. The optical fiber was able to puncture the tumor center in all cases, enabling i-PDT to be performed. Histological analysis showed that tumor necrosis was induced in areas close to the light source, correlating with the irradiation energy dose, whereas apoptosis was induced at some distance from the light source. Irradiation using high energy levels resulted in tissue swelling from strong tumor necrosis, and irradiation at 75 J/cm2 was most suitable for inducing apoptosis. An experimental system of i-PDT using TPS was established using malignant glioma cells transplanted into the rat brain. Tumor cell death, which correlated with the light propagation, was induced in tumor tissue.

31 December 2024 in Neurospine
Verified
Journal Article
Open access
PDF file
TEToshiki Endo
Toshiki Endo
YTYoshiharu Takahashi
Yoshiharu Takahashi
TNTaketo Nishizawa
Taketo Nishizawa
TSTatsuya Sasaki
Tatsuya Sasaki
ASAya Sato
Aya Sato
Jiro AkimotoJiro Akimoto
Jiro Akimoto
Our extensive basic research on photodynamic therapy (PDT) application in models of intracranial malignant astrocytoma led to its clinical application for intracranial malignant astrocytoma in Japan. Having considered the safety and effectiveness of this pathology, we initiate a first-in-human clinical study of PDT for spinal cord malignant astrocytoma. This study has an open-label, single-arm design. The initial follow-up period is 12 months, at the end of which we will quantify survival after PDT for spinal cord malignant astrocytoma as primary objective. The secondary objective is to quantify the overall progression-free survival of treated patients and the percentage of patients surviving 6 months after PDT without recurrence. Twenty patients suffering from spinal cord malignant astrocytoma will be recruited. In particular, 10 of those should be newly diagnosed World Health Organization grade 4. After obtaining consent, each patient will receive a single intravenous injection of talaporfin sodium (40 mg/m2) 1 day before tumor resection. One day after completing tumor removal, the residual lesion and/or resection cavity will be irradiated using a 664-nm semiconductor laser with a radiation power density of 150 mW/cm2 and a radiation energy density of 27 J/cm2. The procedure will be performed 22–26 hours after talaporfin sodium administration. This study protocol has been reviewed and approved by the Certified Committee in the Japanese Ministry of Health, Labor, and Welfare University Hospital Medical Information Network Clinical Trials Registry (Japan Registry of Clinical Trials number, jRCT2021220040).

15 July 2023 in THE JOURNAL OF JAPAN SOCIETY FOR LASER SURGERY AND MEDICINE
Verified
Journal Article
Open access
PDF file
SFShinjiro Fukami
Shinjiro Fukami
JAJiro Akimoto
Jiro Akimoto
KNKenta Nagai
Kenta Nagai
MKMichihiro Kono
Michihiro Kono
悪性神経膠腫に対する光線力学的療法(photodynamic therapy: PDT)につき,照射の工夫・合併症・再発時期や再発パターンを検討した.対象はPDTを施行した106例の画像上悪性神経膠腫と診断した症例で,大きな合併症は1例の爪熱傷であったが,2例脳皮質熱傷が疑われた.再発までの期間の中央値は初発膠芽腫に限ると約12ヶ月で,再発パターンは局所再発が50例で,27例は遠隔部位や播種にて再発した.再発予防としてPDT耐性の腫瘍コントロールが重要と考えられた.

29 May 2025 in Neurosurgical Review
Verified
Journal Article
Open access
PDF file
SFShinjiro Fukami
Shinjiro Fukami
KNKenta Nagai
Kenta Nagai
NNNobuyuki Nakajima
Nobuyuki Nakajima
SOSho Onodera
Sho Onodera
JAJiro Akimoto
Jiro Akimoto
MKMichihiro Kohno
Michihiro Kohno
Purpose: Neuroendoscopic biopsy has various advantages, such as being able to collect larger tissue samples and achieving more efficient hemostasis compared to needle biopsy. The purpose of this study is to review the surgical techniques, accuracy of pathological diagnosis, and perioperative complications of patients with intracerebral malignant lymphoma who were diagnosed mainly by neuroendoscopic biopsy. Methods: A total of 65 patients diagnosed as having malignant lymphoma, via mainly neuroendoscopic biopsy, were analyzed retrospectively. A flexible neuroendoscope was used for ventricular and paraventricular lesions, which was inserted via the lateral ventricle. For intraparenchymal lesions, rigid scopes with navigation systems were used. Results: The main location of the tumors was in the intraventricular/paraventricular regions in 22 patients, in the deep white matter in 22 patients, in the basal ganglia in 14 patients, and in the cerebellum in 5 patients. Two patients had a lymphomatosis cerebri-like lesion. Lymphoma was diagnosed in 58 of the 65 patients, with most patients diagnosed as having diffuse large B-cell lymphoma. Incorrect diagnoses were owing to inappropriate samples, sentinel lesions, or preoperative treatments, such as with steroids. Complications included small cerebral hematoma in 5 patients, severe cerebral edema in 3 patients (2 fatal), and brain abscess and arterial bleeding leading to infarction in 1 case each. Conclusion: Neuroendoscopic biopsy is a reliable diagnostic approach for intracranial malignant lymphomas, particularly those in deep or intraventricular/paraventricular locations. However, caution is particularly required for patients with severe cerebral swelling, which may cause death, and those with prior sentinel lesions.

31 March 2026 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
SFShinjiro Fukami
Shinjiro Fukami
JAJiro Akimoto
Jiro Akimoto
KNKenta Nagai
Kenta Nagai
NNNobuyuki Nakajima
Nobuyuki Nakajima
NINorio Ichimasu
Norio Ichimasu
MKMichihiro Kohno
Michihiro Kohno
Purpose: Atypical and anaplastic (grade 2/3) meningiomas are associated with high recurrence rates and lack effective systemic therapies other than radiotherapy. Photodynamic therapy (PDT) using talaporfin sodium (TPS) generates selective cytotoxicity extending beyond resection margins and may improve local tumor control. Objective is to evaluate the feasibility, safety, and clinical outcomes of additional intraoperative PDT using TPS for grade 2/3 meningioma patients. Methods: Nineteen patients with grade 2/3 meningiomas who underwent resection together with PDT at our institute between 2015 and 2025 were retrospectively analyzed. PDT was performed 22 to 26 h after intravenous TPS administration. Tumor location, pathology, Simpson resection grades, history of radiation therapy (RT), and outcomes were reviewed. Results: Of the 19 patients, 18 had recurrent tumors, and 10 had prior RT. Tumor sites included skull base (8 patients), parasagittal sinus (6), convexity (2), falx (1), subcutaneous (1), and intraventricular (1). Histology revealed grade 2 (12 patients) and grade 3 (7), with Simpson I (3), II (6), III (2), and IV (8) resections. Median progression-free survival was 12.5 months, and median overall survival after PDT was 54.5 months. The prognosis was more favorable in RT- naïve patients than in those with a history of prior RT before PDT. Conclusion: PDT combined with resection is a safe adjunctive strategy for grade 2/3 meningiomas. Our preliminary data suggest that its efficacy is limited in post-radiation recurrences, but it may delay disease progression when applied before RT. PDT should hence be considered as a therapeutic option for grade 2/3 meningiomas.